Article metrics

other Versions

Download PDFPDF

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

 

Online download statistics by month:

Online download statistics by month: November 2021 to January 2022

AbstractFullPdf
Nov 2021455430230
Dec 2021842820318
Jan 202211801200389
Total24772450937